Myth Check: Does Cutting Out a Keloid Always Make It Come Back Worse?

If you have spent any time in keloid support forums, you have seen the warning: never cut out a keloid, because it will grow back bigger. Like most durable myths, this one contains a real kernel of truth wrapped in an oversimplification. The accurate version is narrower and far more actionable: excision alone has a high recurrence rate, but excision combined with adjuvant therapy is a legitimate, evidence-supported strategy for many keloids, especially on the earlobe.

Start with the kernel of truth. Published series consistently report that surgical excision by itself, with no follow-up treatment, leads to recurrence in roughly 45 to 100 percent of cases depending on the site, the patient, and how long researchers followed up. And recurrent keloids can indeed exceed the footprint of the original lesion, because the new surgical wound is often longer than the scar it replaced. So the fear is not invented. It is a reasonable summary of what happens when surgery is used as a standalone fix.

The mechanism explains why. A keloid is not simply excess scar tissue sitting on the skin. It is the visible output of a dysregulated wound healing program. In keloid-prone skin, fibroblasts behave abnormally: they overproduce collagen, particularly type I, they resist the normal signals that tell them to stop, and they show heightened sensitivity to transforming growth factor beta, a signaling protein that drives fibrosis. Cutting out the keloid removes the product but not the program. The excision itself creates a fresh wound, which triggers the same inflammatory and proliferative cascade that produced the keloid in the first place. Without intervention, the biology simply runs again.

This is where the myth breaks down. Modern keloid management rarely uses excision alone. Instead, surgery is paired with an adjuvant, a second treatment aimed at interrupting the healing cascade before it overshoots. The best studied combinations include the following.

Excision plus corticosteroid injection. Triamcinolone injected into the wound edges at surgery and at intervals afterward suppresses inflammation and reduces fibroblast collagen synthesis. Reported recurrence rates with this combination generally fall to around 20 to 50 percent, a meaningful improvement over surgery alone, though results vary widely with injection schedule and patient adherence.

Excision plus radiotherapy. Low-dose superficial radiation delivered within the first day or two after excision targets rapidly dividing fibroblasts during the window when the proliferative phase is beginning. Multiple series report recurrence rates below 20 percent, and some below 10 percent, when timing and dosing are appropriate. Radiation carries its own considerations, including theoretical long-term risks that clinicians weigh against lesion severity, patient age, and body site, which is why it is typically reserved for larger or previously recurrent keloids.

Excision plus pressure therapy. This is most relevant for earlobe keloids, often the result of piercings. Pressure earrings worn consistently for months after excision are thought to work by reducing blood flow and mechanically limiting collagen deposition in the healing wound. Earlobe keloids treated with excision plus sustained pressure show some of the lowest recurrence rates in the keloid literature, which is one reason earlobes are considered a comparatively favorable site for surgery.

Excision plus other injectables. Fluorouracil, sometimes combined with triamcinolone, and other antiproliferative agents have growing evidence behind them, particularly for patients who respond poorly to steroids alone or who develop steroid side effects like skin thinning.

Two practical points get lost when the conversation stays at the level of the myth. First, the adjuvant plan matters as much as the surgery, and it usually requires commitment. Steroid injections may continue monthly for several months. Pressure earrings may need to be worn most of the day for six to twelve months. Patients who stop early because the wound looks fine are stopping precisely when the fibrotic program can still reignite. Recurrence often appears within the first year, so follow-up through that window is part of the treatment, not an optional extra.

Second, not all keloids are equal candidates. Site matters: earlobes tend to respond well, while the chest, shoulders, and upper back, areas under constant skin tension, recur more readily. Tension itself is mechanistically relevant, since mechanical stretch activates fibroblast signaling pathways that promote collagen production. History matters too. A keloid that has already recurred after prior treatment signals more aggressive biology and usually warrants a more intensive adjuvant plan from the outset.

So where does that leave the myth? Retire the absolute version. Cutting out a keloid does not automatically doom you to a bigger one. But keep its cautious spirit: surgery without a plan for what happens during healing is a gamble the biology usually wins. The right question to bring to a consultation is not whether excision is safe in general, but what adjuvant protocol is planned, how long it lasts, and what the recurrence data looks like for your specific lesion and location. Keloid care is a marathon of follow-through, and the patients who do best are usually the ones who treat the months after surgery as seriously as the surgery itself.

Further reading: Analysis of Therapeutic Interventions for Hypertrophic and Keloid Scarring: A Systematic Review (J Drugs Dermatol 2025); Keloid management: a review of treatment modalities (Ital J Dermatol Venerol 2025); Pathogenesis, attenuation, and treatment strategies for keloid management (Tissue Cell 2025).